IP Library › Granted Patent US 11,401,314
Granted Patent B2
US 11,401,314 · App. 17/131,104 · Granted Aug 2, 2022

T-cell modulatory multimeric polypeptides and methods of use thereof

Inventors: Ronald D. Seidel, III (Cambridge, MA); Rodolfo Chaparro (Cambridge, MA)
Assignee: Cue Biopharma, Inc.
C07K14/55A61K9/0019A61K35/17C07K14/005C07K14/4748C07K14/70539G01N33/5008A61K38/00A61K2039/505C07K2317/34C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,401,314
App. No.
17/131,104
Granted
Aug 2, 2022
Kind
B2
Abstract

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Claims (26)

1. A nucleic acid comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence as set forth in SEQ ID NO:72.

2. A nucleic acid comprising:

a first nucleotide sequence encoding a first polypeptide comprising, in order from N-terminus to C-terminus:

i) an HPV16 E7 epitope comprising amino acid sequence YMLDLQPETT (SEQ ID NO:13);

ii) a linker comprising amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:89); and

iii) a β2-microglobulin (β2M) polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:17; and

a second nucleotide sequence encoding a second polypeptide having an amino acid sequence as set forth in SEQ ID NO:72.

3. A nucleic acid according to claim 2 , wherein the nucleic acid comprises (i) a proteolytically cleavable linker interposed between the first nucleotide sequence and the second nucleotide sequence, (ii) an internal ribosome entry site interposed between the first nucleotide sequence and the second nucleotide sequence, or (iii) a ribosome skipping signal or cis-acting hydrolase element interposed between the first nucleotide sequence and second nucleotide sequence.

4. An expression vector comprising the nucleic acid of claim 1 .

5. An expression vector comprising the nucleic acid of claim 2 .

6. An expression vector comprising the nucleic acid of claim 3 .

7. A cell genetically modified with the expression vector of claim 4 .

8. A cell genetically modified with the expression vector of claim 5 .

9. A cell genetically modified with the expression vector of claim 6 .

10. A method comprising culturing a genetically modified cell according to claim 7 in a culture medium under conditions such that the cell synthesizes the polypeptide.

11. A method comprising culturing a genetically modified cell according to claim 8 in a culture medium under conditions such that the cell synthesizes the first and second polypeptides.

12. A method comprising culturing a genetically modified cell according to claim 9 in a culture medium under conditions such that the cell synthesizes the first and second polypeptides.

13. First and second nucleic acids, wherein:

a) the first nucleic acid comprises a nucleotide sequence encoding a first polypeptide comprising, in order from N-terminus to C-terminus:

i) an HPV16 E7 epitope comprising amino acid sequence YMLDLQPETT (SEQ ID NO:13);

ii) a linker comprising amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:89); and

iii) a β2-microglobulin (β2M) polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:17; and

b) the second nucleic acid comprises a nucleotide sequence encoding a second polypeptide having an amino acid sequence as set forth in SEQ ID NO:72.

14. One or more expression vectors comprising the first and second nucleic acids of claim claim 13 .

15. A cell genetically modified with the one or more expression vectors of claim 14 .

16. A method comprising culturing a genetically modified cell according to claim 15 in a culture medium under conditions such that the cell synthesizes the first and second polypeptides.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: SEIDEL, RONALD D., III; CHAPARRO, RODOLFO J.
To: CUE BIOPHARMA, INC.
Reel/Frame 054738/0521 →
Continuity (8)
Division 16812926 · Mar 9, 2020
Continuation 16741202 · Jan 13, 2020
Continuation 16462443
Provisional Application 62582132 · Nov 6, 2017
Provisional Application 62555435 · Sep 7, 2017
Provisional Application 62470774 · Mar 13, 2017
Provisional Application 62438272 · Dec 22, 2016
Related Publication 20210107962A1 · Apr 15, 2021
Cited By (5)
US 12,257,311 US 12,297,249 US 12,421,287 US 12,485,184 US 12,642,840